NasdaqCM - Delayed Quote USD

Alaunos Therapeutics, Inc. (TCRT)

1.3200 +0.1600 (+13.79%)
At close: April 26 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5.0000
5.0000
2,922.0000
398.0000
--
Operating Expense
28,498.0000
28,498.0000
38,160.0000
77,207.0000
80,361.0000
Operating Income
-28,493.0000
-28,493.0000
-35,238.0000
-76,809.0000
-80,361.0000
Net Non Operating Interest Income Expense
-1,921.0000
-1,921.0000
-3,154.0000
-1,189.0000
--
Other Income Expense
-4,726.0000
-4,726.0000
662.0000
-753.0000
385.0000
Pretax Income
-35,140.0000
-35,140.0000
-37,730.0000
-78,751.0000
-79,976.0000
Net Income Common Stockholders
-35,140.0000
-35,140.0000
-37,730.0000
-78,751.0000
-79,976.0000
Diluted NI Available to Com Stockholders
-35,140.0000
-35,140.0000
-37,730.0000
-78,751.0000
-79,976.0000
Basic EPS
-2.25
-33.00
-39.15
-5.55
-5.70
Diluted EPS
-2.25
-33.00
-39.15
-5.55
-5.70
Basic Average Shares
15,716.7020
1,066.3540
965.0230
14,293.2710
13,975.7630
Diluted Average Shares
15,716.7020
1,066.3540
965.0230
14,293.2710
13,975.7630
Total Operating Income as Reported
-34,267.0000
-34,267.0000
-35,105.0000
-77,549.0000
-80,361.0000
Total Expenses
28,498.0000
28,498.0000
38,160.0000
77,207.0000
80,361.0000
Net Income from Continuing & Discontinued Operation
-35,140.0000
-35,140.0000
-37,730.0000
-78,751.0000
-79,976.0000
Normalized Income
-29,366.0000
-29,366.0000
-37,863.0000
-78,011.0000
-79,976.0000
Interest Expense
1,921.0000
1,921.0000
3,154.0000
1,189.0000
--
Net Interest Income
-1,921.0000
-1,921.0000
-3,154.0000
-1,189.0000
--
EBIT
-33,219.0000
-33,219.0000
-34,576.0000
-77,562.0000
-79,976.0000
EBITDA
-30,904.0000
-30,904.0000
-31,817.0000
-74,965.0000
-78,848.0000
Reconciled Depreciation
2,315.0000
2,315.0000
2,759.0000
2,597.0000
1,128.0000
Net Income from Continuing Operation Net Minority Interest
-35,140.0000
-35,140.0000
-37,730.0000
-78,751.0000
-79,976.0000
Total Unusual Items Excluding Goodwill
-5,774.0000
-5,774.0000
133.0000
-740.0000
--
Total Unusual Items
-5,774.0000
-5,774.0000
133.0000
-740.0000
--
Normalized EBITDA
-25,130.0000
-25,130.0000
-31,950.0000
-74,225.0000
-78,848.0000
12/31/2020 - 8/24/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PGEN Precigen, Inc.
1.4100
+0.71%
 
CRMD CorMedix Inc.
5.31
+2.31%
 
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%
 
LUMO Lumos Pharma, Inc.
2.7700
-1.07%
 
BNOX Bionomics Limited
1.0000
+3.49%
 
CYTO Altamira Therapeutics Ltd.
1.6900
+5.63%
 
SYBX Synlogic, Inc.
1.8700
-1.06%
 
ACOGF Alpha Cognition Inc.
0.5100
+3.03%
 
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%
 
SGMO Sangamo Therapeutics, Inc.
0.5178
+2.94%